{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:00:21Z","timestamp":1785427221627,"version":"3.56.0"},"reference-count":198,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2013460"],"award-info":[{"award-number":["GNT2013460"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"award":["GNT2013460"],"award-info":[{"award-number":["GNT2013460"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001787","name":"University of South Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001787","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Flinders Foundation Cancer"},{"id":[{"id":"https:\/\/ror.org\/045thxk12","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple Myeloma (MM) is a hematological malignancy characterized by the clonal proliferation and survival of neoplastic plasma cells (PCs) within the bone marrow (BM), where disease progression is critically supported by interactions with the BM tumor microenvironment (TME). Despite significant advances in therapeutic strategies, MM remains incurable, underscoring the need for improved preclinical models to better understand the disease biology and therapeutic response. This review summarizes current and emerging MM treatment approaches and critically examines the development of models designed to more accurately recapitulate interactions between MM-PCs and the surrounding BM niche. We describe established and emerging modeling platforms, with emphasis on advanced three-dimensional (3D) culture systems and highlight their unique contributions to the preclinical assessment of both existing and novel therapies. The advantages of 3D models, including in vitro and in silico systems, over traditional two-dimensional (2D) models are discussed, alongside a comparative evaluation of scaffold-free and scaffold-based approaches. In addition, the benefits and recent advances in the customization of BM niche simulation using microfluidic technologies and organ-on-a-chip platforms are reviewed. The application of 3D models in MM research is increasingly enabling the study of disease pathogenesis, progression, drug resistance and precision-medicine approaches (informed by biomarker discovery). Although standardized preclinical approaches for evaluating MM therapeutics are currently lacking, the growing imperative to reduce reliance on preclinical animal models highlights the importance of alternate systems. Consequently, the development and adoption of physiologically relevant models that accurately recapitulate MM-PC interactions with the BM TME will be critical for advancing future therapeutic strategies in MM.<\/jats:p>","DOI":"10.3390\/cancers18132050","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:03:56Z","timestamp":1782349436000},"page":"2050","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Modeling Multiple Myeloma Within the Bone Marrow Tumor Microenvironment for Exploration of Current and Emerging Therapies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7458-836X","authenticated-orcid":false,"given":"Charlotte E. J.","family":"Toomes","sequence":"first","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2685-3880","authenticated-orcid":false,"given":"Oliver G.","family":"Best","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hollenberg","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Turner","sequence":"additional","affiliation":[{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia"},{"name":"Department of Haematology, Flinders Medical Centre, Bedford Park, SA 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9875-967X","authenticated-orcid":false,"given":"Claudine S.","family":"Bonder","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, College of Health, Adelaide University, Adelaide, SA 5000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5201-4127","authenticated-orcid":false,"given":"Barbara J.","family":"McClure","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, College of Health, Adelaide University, Adelaide, SA 5000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Diao, X., Ben, T., Cheng, S., Niu, S., Gao, L., and Xia, N. (2025). Global, regional, and national multiple myeloma burden from 1990 to 2021: A systematic analysis for of the Global Burden of Disease Study 2021. BMC Public Health, 25.","DOI":"10.1186\/s12889-025-22240-2"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: A global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_5","first-page":"2203","article-title":"Doubling in median survival in patients diagnosed with multiple myeloma 2005-2019; a real-world study from the UK\u2019s Haematological Malignancy Research Network","volume":"110","author":"Smith","year":"2020","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Garcia-Ortiz, A., Rodriguez-Garcia, Y., Encinas, J., Maroto-Martin, E., Castellano, E., Teixido, J., and Martinez-Lopez, J. (2021). The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers, 13.","DOI":"10.3390\/cancers13020217"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e420064a","DOI":"10.1097\/01.HS9.0000970728.42006.4a","article-title":"P956: Validation of the Second Revision of the International Staging System (R2-Iss) for Overall Survival in Multiple Myeloma in a Real World Cohort: An Analysis by the Balkan Myeloma Study Group (BMSG)","volume":"7","author":"Kastritis","year":"2023","journal-title":"HemaSphere"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma","volume":"43","author":"Davies","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jmoldx.2025.01.003","article-title":"Deciphering Genomic Complexity of Multiple Myeloma Using Optimized Optical Genome Mapping","volume":"27","author":"Guermouche","year":"2025","journal-title":"J. Mol. Diagn."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lee, C.H., Zhang, Y., McClure, B.J., Yong, A., Scott, H.S., and Kok, C.H. (2026). Shaping the future of multiple myeloma with artificial intelligence and digital twins: From concept to clinic. Front. Digit. Health, 8.","DOI":"10.3389\/fdgth.2026.1771531"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/ajh.70070","article-title":"European Myeloma Network Consensus Statement on Functional High-Risk Multiple Myeloma","volume":"100","author":"Lim","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e941742","DOI":"10.4161\/21624011.2014.941742","article-title":"Lenalidomide induces degradation of IKZF1 and IKZF3","volume":"3","author":"Hurst","year":"2014","journal-title":"OncoImmunology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/leu.2011.214","article-title":"Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma","volume":"26","author":"Kamps","year":"2012","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/bloodadvances.2021006638","article-title":"Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects","volume":"7","author":"Li","year":"2023","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Besliu, C., Tanase, A.D., Rotaru, I., Espinoza, J., Vidal, L., Poelman, M., Juan, M., de Larrea, C.F., and Saini, K.S. (2025). The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies. Cancers, 17.","DOI":"10.3390\/cancers17030525"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: Unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_29","first-page":"239","article-title":"Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials","volume":"38","author":"Avigan","year":"2024","journal-title":"Oncology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","article-title":"Targeting Bcl-2 for the treatment of multiple myeloma","volume":"32","author":"Touzeau","year":"2018","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1200\/JCO.2024.42.16_suppl.7510","article-title":"Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed\/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis","volume":"42","author":"Bahlis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Medina-Herrera, A., Sarasquete, M.E., Jim\u00e9nez, C., Puig, N., and Garc\u00eda-Sanz, R. (2023). Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future. Cancers, 15.","DOI":"10.3390\/cancers15143687"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.18632\/oncotarget.27973","article-title":"Developing next generation immunomodulatory drugs and their combinations in multiple myeloma","volume":"12","author":"Thakurta","year":"2021","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1878-0261.13055","article-title":"Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma","volume":"16","author":"Ebert","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2474271","DOI":"10.1080\/16078454.2025.2474271","article-title":"Downregulated expression of dual-specificity phosphatase-1 in multiple myeloma as a predictor of poor survival outcomes","volume":"30","author":"Guo","year":"2025","journal-title":"Hematology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-025-01230-y","article-title":"High WEE1 expression is independently linked to poor survival in multiple myeloma","volume":"15","author":"Simhal","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Rajput, S.K., Minhas, K., Azam, I., Habib, S., Shaikh, U., and Lalani, E.-N. (2025). Prognostic implications of MUC1 and XBP1 concordant expression in multiple myeloma: A retrospective study. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0320934"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"110474","DOI":"10.1016\/j.clim.2025.110474","article-title":"An analysis of the clinical value of CHI3L1 as a biomarker of multiple myeloma progression","volume":"275","author":"Tang","year":"2025","journal-title":"Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41408-024-01185-6","article-title":"High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis","volume":"14","author":"Martello","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3343\/alm.2024.0424","article-title":"Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor Diseases","volume":"45","author":"Park","year":"2025","journal-title":"Ann. Lab. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood-2003-04-1338","article-title":"Endothelial cells in the bone marrow of patients with multiple myeloma","volume":"102","author":"Vacca","year":"2003","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.leu.2402717","article-title":"Expression and function of chemokine receptors in human multiple myeloma","volume":"17","author":"Juremalm","year":"2003","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)\u2013dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2006","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1084\/jem.194.1.45","article-title":"A Coordinated Change in Chemokine Responsiveness Guides Plasma Cell Movements","volume":"194","author":"Hargreaves","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \u201cBRCAness\u201d sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2003-08-2946","article-title":"Angiogenic switch during 5T2MM murine myeloma tumorigenesis: Role of CD45 heterogeneity","volume":"103","author":"Asosingh","year":"2004","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4248\/BR201304002","article-title":"Skeletal Blood Flow in Bone Repair and Maintenance","volume":"1","author":"Tomlinson","year":"2013","journal-title":"Bone Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature13145","article-title":"Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone","volume":"507","author":"Kusumbe","year":"2014","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41413-021-00138-0","article-title":"Skeleton-vasculature chain reaction: A novel insight into the mystery of homeostasis","volume":"9","author":"Chen","year":"2021","journal-title":"Bone Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2013-07-517136","article-title":"Osteoblastic niche supports the growth of quiescent multiple myeloma cells","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug\u2013induced apoptosis","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"11283","DOI":"10.18632\/oncotarget.2207","article-title":"Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4\/CXCL12 axis and promote their polarization toward the M2 phenotype","volume":"5","author":"Beider","year":"2014","journal-title":"Oncotarget"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/leu.2012.272","article-title":"PSGL-1\/selectin and ICAM-1\/CD18 interactions are involved in macrophage-induced drug resistance in myeloma","volume":"27","author":"Zheng","year":"2013","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00262-014-1646-4","article-title":"Tumor-induced CD14+HLA-DR\u2212\/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients","volume":"64","author":"Wang","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.18632\/oncotarget.3300","article-title":"Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells","volume":"6","author":"Veirman","year":"2015","journal-title":"Oncotarget"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical stage-depending decrease of NK cell activity in multiple myeloma patients","volume":"24","author":"Jurisic","year":"2007","journal-title":"Med. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3324\/haematol.2016.154062","article-title":"Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression","volume":"102","author":"Jianan","year":"2017","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/onc.2008.385","article-title":"Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma","volume":"28","author":"Hatano","year":"2009","journal-title":"Oncogene"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.leu.2402336","article-title":"CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells","volume":"16","author":"Joling","year":"2002","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.bbrc.2005.09.146","article-title":"Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease","volume":"338","author":"Heider","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"E3053","DOI":"10.1073\/pnas.1411082111","article-title":"Platelets guide the formation of early metastatic niches","volume":"111","author":"Labelle","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1158\/1078-0432.CCR-17-2003","article-title":"Platelets Enhance Multiple Myeloma Progression via IL-1\u03b2 Upregulation","volume":"24","author":"Takagi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Ito, S. (2020). Proteasome Inhibitors for the Treatment of Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12020265"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/14728214.2025.2575570","article-title":"Mezigdomide for multiple myeloma: A focus on phase 2 trial data","volume":"30","author":"Mo","year":"2025","journal-title":"Expert. Opin. Emerg. Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., and Zhou, K. (2022). Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1017990"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","article-title":"Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication","volume":"21","author":"Mathieu","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcancer.2021.05.032","article-title":"Extracellular vesicles in cancer progression","volume":"76","author":"Ortiz","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.2021014749","article-title":"Exosomes in multiple myeloma: From bench to bedside","volume":"140","author":"Menu","year":"2022","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Botta, C., Mendicino, F., Martino, E.A., Vigna, E., Ronchetti, D., Correale, P., Morabito, F., Neri, A., and Gentile, M. (2021). Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities. Cancers, 13.","DOI":"10.3390\/cancers13133213"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Louren\u00e7o, D., Lopes, R., Pestana, C., Queir\u00f3s, A.C., Jo\u00e3o, C., and Carneiro, E.A. (2022). Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine\u2014Are We There Yet?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112888"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"104233","DOI":"10.1016\/j.exphem.2024.104233","article-title":"Complexities of modeling the bone marrow microenvironment to facilitate hematopoietic research","volume":"135","author":"Busch","year":"2024","journal-title":"Exp. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.3390\/ijms16035517","article-title":"Three-Dimensional Cell Culture: A Breakthrough in Vivo","volume":"16","author":"Antoni","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1152\/physiol.00036.2016","article-title":"Modeling Physiological Events in 2D vs. 3D Cell Culture","volume":"32","author":"Duval","year":"2017","journal-title":"Physiology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/joa.12257","article-title":"Advances in 3D cell culture technologies enabling tissue-like structures to be created in vitro","volume":"227","author":"Knight","year":"2015","journal-title":"J. Anat."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.tcb.2011.09.005","article-title":"From 3D cell culture to organs-on-chips","volume":"21","author":"Huh","year":"2011","journal-title":"Trends Cell Biol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Haycock, J.W. (2011). 3D Cell Culture: A Review of Current Approaches and Techniques. 3D Cell Culture: Methods and Protocols, Humana Press.","DOI":"10.1007\/978-1-60761-984-0"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.exphem.2007.06.016","article-title":"Characterization of in vitro growth of multiple myeloma cells","volume":"35","author":"Zlei","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Papadimitriou, K., Kostopoulos, I.V., Tsopanidou, A., Orologas-Stavrou, N., Kastritis, E., Tsitsilonis, O.E., Dimopoulos, M.A., and Terpos, E. (2020). Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12082006"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e175824","DOI":"10.1172\/JCI175824","article-title":"FDA Modernization Act 2.0: Transitioning beyond animal models with human cells, organoids, and AI\/ML-based approaches","volume":"133","author":"Zushin","year":"2023","journal-title":"J. Clin. Invest."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.ejca.2005.12.025","article-title":"The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions","volume":"42","author":"Mitsiades","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12026-014-8528-x","article-title":"Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma","volume":"59","author":"Rosean","year":"2014","journal-title":"Immunol. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1038\/s41375-020-0785-1","article-title":"Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis","volume":"34","author":"Sarin","year":"2020","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1535-6108(04)00050-9","article-title":"Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors","volume":"5","author":"Mitsiades","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Bam, R., Khan, S., Ling, W., Randal, S.S., Li, X., Barlogie, B., Edmondson, R., and Yaccoby, S. (2015). Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1892-7"},{"key":"ref_95","first-page":"192","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model","volume":"91","author":"Yaccoby","year":"2006","journal-title":"Haematologica"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.4161\/onci.21058","article-title":"High-throughput approaches to discover novel immunomodulatory agents for cancer","volume":"1","author":"McMillin","year":"2012","journal-title":"OncoImmunology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1365-2141.1998.00517.x","article-title":"Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: Studies with primary tumour cells and LTBMC-dependent cell lines","volume":"100","author":"Bloem","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood.V77.12.2688.2688","article-title":"\u2019Role of Bone Marrow Stromal Cells in the Growth of Human Multiple Myeloma","volume":"77","author":"Cappio","year":"1991","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1182\/blood-2014-02-558007","article-title":"Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model","volume":"124","author":"Reagan","year":"2014","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhang, W., Gu, Y., Sun, Q., Siegel, D.S., Tolias, P., Yang, Z., Lee, W.Y., and Zilberberg, J. (2015). Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125995"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/0008-5472.CAN-03-1131","article-title":"Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model","volume":"64","author":"Yaccoby","year":"2004","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1038\/emm.2013.2","article-title":"The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation","volume":"45","author":"Kim","year":"2013","journal-title":"Exp. Mol. Med."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Maiso, P., Mogoll\u00f3n, P., Ocio, E.M., and Garayoa, M. (2021). Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression. Cancers, 13.","DOI":"10.3390\/cancers13112542"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41419-018-0545-6","article-title":"Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells","volume":"9","author":"Guo","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/stem.2499","article-title":"A Lysophosphatidic Acid Receptors 1 and 3 Axis Governs Cellular Senescence of Mesenchymal Stromal Cells and Promotes Growth and Vascularization of Multiple Myeloma","volume":"35","author":"Kanehira","year":"2017","journal-title":"Stem Cells"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","article-title":"Adhesion of Human Myeloma-Derived Cell Lines to Bone Marrow Stromal Cells Stimulates Interleukin-6 Secretion","volume":"82","author":"Uchiyama","year":"1993","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00005-008-0022-5","article-title":"Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells","volume":"56","year":"2008","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8284","DOI":"10.18632\/oncotarget.2058","article-title":"Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease","volume":"5","author":"Rivas","year":"2014","journal-title":"Oncotarget"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bone.2016.08.006","article-title":"Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells \u2013Implications for myeloma bone disease","volume":"93","author":"Dotterweich","year":"2016","journal-title":"Bone"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Knowles, H.J. (2017). Multiple Roles of Angiopoietin-Like 4 in Osteolytic Disease. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00080"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2011-11-393348","article-title":"Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment","volume":"119","author":"Kurihara","year":"2012","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1541-7786.MCR-16-0242-T","article-title":"EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma\u2013Induced Epigenetic Suppression of Osteoblast Differentiation","volume":"15","author":"Adamik","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jbo.2018.09.001","article-title":"Osteoblast suppression in multiple myeloma bone disease","volume":"13","author":"Adamik","year":"2018","journal-title":"J. Bone Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41467-020-20715-x","article-title":"Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1002\/jcp.25351","article-title":"Current Controversies in the Management of Myeloma Bone Disease","volume":"231","author":"Silbermann","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e10183","DOI":"10.1002\/jbm4.10183","article-title":"Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease","volume":"3","author":"Adamik","year":"2019","journal-title":"JBMR Plus"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Xu, S., Cecilia Santini, G., De Veirman, K., Vande Broek, I., Leleu, X., De Becker, A., Van Camp, B., Vanderkerken, K., and Van Riet, I. (2013). Upregulation of miR-135b Is Involved in the Impaired Osteogenic Differentiation of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079752"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/s41375-018-0161-6","article-title":"Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche","volume":"32","author":"Tsukamoto","year":"2018","journal-title":"Leukemia"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Raimondi, L., De Luca, A., Giavaresi, G., Raimondo, S., Gallo, A., Taiana, E., Alessandro, R., Rossi, M., Neri, A., and Viglietto, G. (2020). Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology. Non-Coding RNA, 6.","DOI":"10.3390\/ncrna6030037"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"27343","DOI":"10.18632\/oncotarget.4398","article-title":"Inhibition of miR-21 restores RANKL\/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts","volume":"6","author":"Pitari","year":"2015","journal-title":"Oncotarget"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2016.04.024","article-title":"Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity","volume":"377","author":"Wang","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"9012152","DOI":"10.1155\/2017\/9012152","article-title":"Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a","volume":"2017","author":"Cheng","year":"2017","journal-title":"Stem Cells Int."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Raimondo, S., Urz\u00ec, O., Conigliaro, A., Lo Bosco, G., Parisi, S., Carlisi, M., Siragusa, S., Raimondi, L., De Luca, A., and Giavaresi, G. (2020). Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12020449"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"106458","DOI":"10.1016\/j.compbiomed.2022.106458","article-title":"Computational modeling of multiple myeloma interactions with resident bone marrow cells","volume":"153","author":"Urdeitx","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.18632\/oncotarget.6151","article-title":"Disentangling the microRNA regulatory milieu in multiple myeloma: Integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients","volume":"7","author":"Calura","year":"2015","journal-title":"Oncotarget"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/0008-5472.CAN-17-0115","article-title":"HIF-2\u03b1 Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12\/CXCR4 and CCR1","volume":"77","author":"Vandyke","year":"2017","journal-title":"Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2013.090977","article-title":"Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells","volume":"99","author":"Jacqueline","year":"2014","journal-title":"Haematologica"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ijc.33547","article-title":"Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients","volume":"149","author":"Macauda","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1182\/blood-2018-99-112237","article-title":"Altering Glycosphingolipid Composition to Improve Multiple Myeloma Bone Complication","volume":"132","author":"Leng","year":"2018","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbrc.2018.02.103","article-title":"In silico screening of proteins targeting circulating miRNAs for improved diagnosis of multiple myeloma","volume":"497","author":"Suyal","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"14814","DOI":"10.18632\/oncotarget.7442","article-title":"Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma","volume":"7","author":"Ronchetti","year":"2016","journal-title":"Oncotarget"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Caracciolo, D., Riillo, C., Juli, G., Scionti, F., Todoerti, K., Poler\u00e0, N., Grillone, K., Fiorillo, L., Arbitrio, M., and Di Martino, M.T. (2021). miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13174365"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41416-022-02065-1","article-title":"Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival","volume":"128","author":"Nedal","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12032-022-01651-w","article-title":"In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma","volume":"39","author":"Ghosal","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"19331","DOI":"10.1038\/s41598-025-03132-2","article-title":"The 3D genome of plasma cells in multiple myeloma","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-19-2309","article-title":"Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma","volume":"26","author":"Perumal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"Kellermayer","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00277-018-3296-7","article-title":"Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw","volume":"97","author":"Musolino","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Verbruggen, S.W., Freeman, C.L., and Freeman, F.E. (2024). Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells\u2019 Escape from the Bone Marrow Microenvironment. Cancers, 16.","DOI":"10.3390\/cancers16050889"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Urdeitx, P., Clara-Trujillo, S., Gomez Ribelles, J.L., and Doweidar, M.H. (2023). Multiple Myeloma Cell Simulation Using an Agent-Based Framework Coupled with a Continuous Fluid Model. Mathematics, 11.","DOI":"10.3390\/math11081824"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/s41375-025-02712-5","article-title":"The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma","volume":"39","author":"Wang","year":"2025","journal-title":"Leukemia"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/2643-3230.BCD-25-0334","article-title":"Multiplexed Imaging Reveals Immune-Metabolic Niches in Multiple Myeloma Linked to Progression and Bone Disease","volume":"7","author":"Roseth","year":"2026","journal-title":"Blood Cancer Discov."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.2025028896","article-title":"Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics","volume":"146","author":"Yip","year":"2025","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/0008-5472.CAN-22-2654","article-title":"Deep Learning Enables Spatial Mapping of the Mosaic Microenvironment of Myeloma Bone Marrow Trephine Biopsies","volume":"84","author":"Hagos","year":"2024","journal-title":"Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/wsbm.1356","article-title":"In silico bone mechanobiology: Modeling a multifaceted biological system","volume":"8","author":"Giorgi","year":"2016","journal-title":"WIREs Syst. Biol. Med."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Grieb, N., Schmierer, L., Kim, H.U., Strobel, S., Schulz, C., Meschke, T., Kubasch, A.S., Brioli, A., Platzbecker, U., and Neumuth, T. (2023). A digital twin model for evidence-based clinical decision support in multiple myeloma treatment. Front. Digit. Health, 5.","DOI":"10.3389\/fdgth.2023.1324453"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e10228","DOI":"10.1002\/jbm4.10228","article-title":"In Vitro 3D Cultures to Reproduce the Bone Marrow Niche","volume":"3","author":"Ham","year":"2019","journal-title":"JBMR Plus"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2008-02-142430","article-title":"A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma","volume":"112","author":"Kirshner","year":"2008","journal-title":"Blood"},{"key":"ref_150","first-page":"69","article-title":"A comparison of cytokine production in 2-dimensional and 3-dimensional cultures of bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells","volume":"47","author":"Piersiak","year":"2009","journal-title":"Folia Histochem. Cytobiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/leu.2010.300","article-title":"A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells","volume":"25","author":"Calimeri","year":"2011","journal-title":"Leukemia"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/0008-5472.CAN-13-2397","article-title":"A Preclinical Assay for Chemosensitivity in Multiple Myeloma","volume":"74","author":"Khin","year":"2014","journal-title":"Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Ferrarini, M., Steimberg, N., Ponzoni, M., Belloni, D., Berenzi, A., Girlanda, S., Caligaris-Cappio, F., Mazzoleni, G., and Ferrero, E. (2013). Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCCS\u2122 Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy. PLoS ONE, 8.","DOI":"10.1371\/annotation\/d7d8e0a7-aa3d-4620-98e5-c5a7bbf31dc8"},{"key":"ref_154","first-page":"67","article-title":"Characterization of multiple myeloma clonal cell expansion and stromal Wnt\/\u03b2-catenin signaling in hyaluronic acid-based 3D hydrogel","volume":"28","author":"Narayanan","year":"2014","journal-title":"In Vivo"},{"key":"ref_155","first-page":"e50947","article-title":"A Three-dimensional Tissue Culture Model to Study Primary Human Bone Marrow and its Malignancies","volume":"85","author":"Parikh","year":"2014","journal-title":"J. Vis. Exp."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.biomaterials.2015.09.017","article-title":"3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma","volume":"73","author":"Muz","year":"2015","journal-title":"Biomaterials"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2217\/fon-2016-0057","article-title":"3D Tissue-Engineered Bone Marrow: What does this Mean for the Treatment of Multiple Myeloma?","volume":"12","author":"Azab","year":"2016","journal-title":"Future Oncol."},{"key":"ref_158","first-page":"e52665","article-title":"Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis","volume":"99","author":"Martowicz","year":"2015","journal-title":"J. Vis. Exp."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/ten.tec.2013.0490","article-title":"Patient-Specific 3D Microfluidic Tissue Model for Multiple Myeloma","volume":"20","author":"Zhang","year":"2013","journal-title":"Tissue Eng. Part C Methods"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"77326","DOI":"10.18632\/oncotarget.12643","article-title":"A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: Biologic and clinical applications","volume":"7","author":"Jakubikova","year":"2016","journal-title":"Oncotarget"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.yexcr.2017.09.012","article-title":"SAHA-induced TRAIL-sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture","volume":"360","author":"Arhoma","year":"2017","journal-title":"Exp. Cell Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.18632\/oncotarget.13831","article-title":"Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model","volume":"8","author":"Ji","year":"2016","journal-title":"Oncotarget"},{"key":"ref_163","first-page":"e53070","article-title":"An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells","volume":"101","author":"Silva","year":"2015","journal-title":"J. Vis. Exp."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/hon.2306","article-title":"Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system","volume":"35","author":"Bonomi","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Huang, Y.-H., Molavi, O., Alshareef, A., Haque, M., Wang, Q., Chu, M.P., Venner, C.P., Sandhu, I., Peters, A.C., and Lavasanifar, A. (2018). Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model. Cancers, 10.","DOI":"10.20944\/preprints201803.0151.v2"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e1434465","DOI":"10.1080\/2162402X.2018.1434465","article-title":"Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model","volume":"7","author":"Braham","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"8105","DOI":"10.2147\/IJN.S184262","article-title":"Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma","volume":"13","author":"Braham","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1089\/ten.tec.2017.0467","article-title":"Endosteal and Perivascular Subniches in a 3D Bone Marrow Model for Multiple Myeloma","volume":"24","author":"Braham","year":"2018","journal-title":"Tissue Eng. Part C Methods"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.3324\/haematol.2018.213355","article-title":"Possibilities and limitations of an in vitro three-dimensional bone marrow model for the prediction of clinical responses in patients with relapsed multiple myeloma","volume":"104","author":"Maaike","year":"2019","journal-title":"Haematologica"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3324\/haematol.2017.167486","article-title":"Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment","volume":"103","author":"Belloni","year":"2018","journal-title":"Haematologica"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-019-0714-9","article-title":"Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma","volume":"12","author":"Siciliano","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.mtbio.2019.100040","article-title":"A worm gel-based 3D model to elucidate the paracrine interaction between multiple myeloma and mesenchymal stem cells","volume":"5","author":"Spelat","year":"2020","journal-title":"Mater. Today Bio"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Caillot, M., Zylbersztejn, F., Maitre, E., Bourgeais, J., H\u00e9rault, O., and Sola, B. (2020). ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance. Cells, 9.","DOI":"10.3390\/cells9112357"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2100884","DOI":"10.1002\/adhm.202100884","article-title":"A 3D-Bioprinted Multiple Myeloma Model","volume":"11","author":"Wu","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/cimb43010026","article-title":"Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism","volume":"43","author":"Huang","year":"2021","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"19343","DOI":"10.1038\/s41598-021-98760-9","article-title":"A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma","volume":"11","author":"Alhallak","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/jbmr.4404","article-title":"A functional three-dimensional microphysiological human model of myeloma bone disease","volume":"36","author":"Visconti","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"212749","DOI":"10.1016\/j.bioadv.2022.212749","article-title":"Novel microgel culture system as semi-solid three-dimensional in vitro model for the study of multiple myeloma proliferation and drug resistance","volume":"135","author":"Tolosa","year":"2022","journal-title":"Biomater. Adv."},{"key":"ref_180","first-page":"1793","article-title":"Epigenetic Modifications of the Bone Marrow (BM) Niche in Multiple Myeloma (MM)-a Three-Dimensional (3D) in Vitro Approach","volume":"130","author":"Wider","year":"2017","journal-title":"Blood"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00432-021-03854-6","article-title":"Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma","volume":"148","author":"Waldschmidt","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/2159-8290.CD-22-0199","article-title":"Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies","volume":"13","author":"Khan","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41419-024-07038-1","article-title":"In vitro models of the crosstalk between multiple myeloma and stromal cells recapitulate the mild NF-\u03baB activation observed in vivo","volume":"15","author":"Colombo","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/ten.tec.2023.0374","article-title":"Liquid Overlay and Collagen-Based Three-Dimensional Models for In Vitro Investigation of Multiple Myeloma","volume":"30","author":"Ilic","year":"2024","journal-title":"Tissue Eng. Part C Methods"},{"key":"ref_185","first-page":"321","article-title":"A High-Throughput, Three-Dimensional Multiple Myeloma Model Recapitulating Tumor-Stroma Interactions for CAR-Immune Cell-Mediated Cytotoxicity Assay","volume":"14","author":"Luanpitpong","year":"2025","journal-title":"ImmunoTargets Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"123016","DOI":"10.1016\/j.biomaterials.2024.123016","article-title":"Multi-niche human bone marrow on-a-chip for studying the interactions of adoptive CAR-T cell therapies with multiple myeloma","volume":"316","author":"Ghoshal","year":"2025","journal-title":"Biomaterials"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"214243","DOI":"10.1016\/j.bioadv.2025.214243","article-title":"Co-culture of multiple myeloma cell lines and bone marrow mesenchymal stem cells in a 3D microgel environment","volume":"172","author":"Tolosa","year":"2025","journal-title":"Biomater. Adv."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jcp.24683","article-title":"3D Cell Culture Systems: Advantages and Applications","volume":"230","author":"Ravi","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Capp, J.P., and Bataille, R. (2023). The Ins and Outs of Endosteal Niche Disruption in the Bone Marrow: Relevance for Myeloma Oncogenesis. Biology, 12.","DOI":"10.3390\/biology12070990"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12929-024-00994-y","article-title":"Scaffold-based 3D cell culture models in cancer research","volume":"31","author":"Abuwatfa","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Janagama, D., and Hui, S.K. (2020). 3-D Cell Culture Systems in Bone Marrow Tissue and Organoid Engineering, and BM Phantoms as In Vitro Models of Hematological Cancer Therapeutics\u2014A Review. Materials, 13.","DOI":"10.3390\/ma13245609"},{"key":"ref_192","first-page":"278","article-title":"3D bioactive composite scaffolds for bone tissue engineering","volume":"3","author":"Turnbull","year":"2018","journal-title":"Bioact. Mater."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.matt.2022.06.003","article-title":"Scaffolds for bone-tissue engineering","volume":"5","author":"Lee","year":"2022","journal-title":"Matter"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"121568","DOI":"10.1016\/j.biomaterials.2022.121568","article-title":"Current insights into the bone marrow niche: From biology in vivo to bioengineering ex vivo","volume":"286","author":"Xiao","year":"2022","journal-title":"Biomaterials"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/1538-7445.AM2022-283","article-title":"Abstract 283: Reconstructed plate-based 3D screening assays that predict in vivo responses","volume":"82","author":"Urs","year":"2022","journal-title":"Cancer Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"136126","DOI":"10.1016\/j.ijbiomac.2024.136126","article-title":"Synthetic and natural polymer hydrogels: A review of 3D spheroids and drug delivery","volume":"280","author":"Yadav","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Sun, J., Muz, B., Alhallak, K., Markovic, M., Gurley, S., Wang, Z., Guenthner, N., Wasden, K., Fiala, M., and King, J. (2020). Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12020305"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-17-0502","article-title":"An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma","volume":"77","author":"Silva","year":"2017","journal-title":"Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2050\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:00:15Z","timestamp":1782536415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":198,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132050"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132050","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}